Suddenly, cannabis-related, hemp-derived CBD is almost everywhere. CBD’s FDA status is murky, and we know very little about its benefits, thanks in part to its former place on DEA Schedule 1. How much has been proven about its supposed health qualities? What are the risks? Experts discuss in depth.
Guest Information:
- Joanne, Florida RN and CBD user
- Dr. Yasmin Hurd, Director, Addiction Institute, Icahn School of Medicine at Mount Sinai, New York
- Don Ballou, founder and CEO, CBD Essence Products
- Dr. Tim Welty, Director, Research, Innovation and International Programs, College of Pharmacy and Health Sciences, Drake University
The State of the World’s Children
»
Leave a Reply